High-Priced Drugs For Rare Disease: Leading US Payers Discuss Cost Concerns, Value-Based Contracts And ICER

There are as many rare disease patients as there are diabetics, Cigna’s Steve Miller notes, arguing that exorbitant prices for each treatment could drive counterproductive categorical exclusions by payers.